Back to Search
Start Over
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
- Source :
- Leukemia. 28:50-58
- Publication Year :
- 2013
- Publisher :
- Springer Science and Business Media LLC, 2013.
-
Abstract
- Conventionally, acute myeloid leukemia (AML) patients are categorized into good-, intermediate- and poor-risk groups according to cytogenetic changes. However, patients with intermediate-risk cytogenetics represent a largely heterogeneous population regarding treatment response and clinical outcome. In this study, we integrated cytogenetics and molecular mutations in the analysis of 318 patients with de novo non-M3 AML who received standard chemotherapy. According to the mutation status of eight genes, including NPM1, CEBPA, IDH2, RUNX1, WT1, ASXL1, DNMT3A and FLT3, that had prognostic significance, 229 patients with intermediate-risk cytogenetics could be refinedly stratified into three groups with distinct prognosis (P
- Subjects :
- Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
NPM1
Adolescent
medicine.medical_treatment
Biology
IDH2
Young Adult
chemistry.chemical_compound
Risk Factors
Internal medicine
Genotype
CEBPA
medicine
Humans
Aged
Aged, 80 and over
Chromosome Aberrations
Chemotherapy
Cytogenetics
Myeloid leukemia
Hematology
Middle Aged
Leukemia, Myeloid, Acute
RUNX1
chemistry
Mutation
Immunology
Female
Nucleophosmin
Subjects
Details
- ISSN :
- 14765551 and 08876924
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Leukemia
- Accession number :
- edsair.doi.dedup.....bac95046e25a230cad5e681183aa2a62